Plain-English translation of NCT06221683 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether doctors can improve treatment for childhood acute myeloid leukemia (a serious blood cancer) by personalizing chemotherapy based on the genetic mutations in each child's cancer cells. Some children will receive standard-dose chemotherapy, while others receive lower-dose chemotherapy, depending on their cancer's genetics. The study also tests whether adding targeted drugs like , , or to chemotherapy improves results.
Previous research showed that different types of childhood leukemia respond differently to chemotherapy, and that checking how much cancer remains after the first round of treatment helps predict outcomes. This trial aims to use that information to give each child the best chemotherapy approach for their specific cancer, hopefully improving survival and reducing side effects.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy in the hospital over several weeks, with your specific drug doses and combination determined by genetic testing of your cancer cells and how you respond after the first treatment cycle. Some children may receive additional targeted medications along with chemotherapy. After the initial treatment phase, you will receive additional chemotherapy cycles to consolidate the response, and depending on your risk category, you may be candidates for a bone marrow transplant. You will have regular blood tests and monitoring throughout treatment to assess how your cancer is responding.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China